Cereno Scientific

The article published in Blood shows that CS585, a prostacyclin receptor agonist, is a highly potent and selective compound given both orally and intravenously preventing thrombosis for up to 48 hours after dosing as observed in preclinical studies. The publication titled “The oxylipin analogue CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptor”, was authored by L. Stanger et al. Michael Holinstat is the inventor of CS585 and leads its development program at the University of Michigan.  

Blood Podcast is described as a source of innovative ideas and cutting-edge information with topics based on articles published in Blood, a journal by the American Society of Hematology. In this episode, Blood Podcast highlights the promise of drug candidate CS585 introducing the paper as: “Targeting the prostacyclin receptor is a promising strategy for regulating hemostasis and thrombosis. Now, a novel analog [CS585] of a recently discovered platelet oxylipin is shown to selectively inhibit platelet activation but without the bleeding risk and off-target activation seen with previous prostacyclin receptor agonists.”

“CS585 will enable us for the first time to think about targeting the IP receptor in blood due to its selectivity, potency, and stability. Based on the safety profile and oral availability described in our Blood paper, CS585 is a very attractive compound for development as an antiplatelet thrombotic drug without an increased risk for bleeding,” said Michael Holinstat, co-author of the Blood paper, inventor of CS585, lead of Cereno’s development programs at the University of Michigan and Director of Translational Research at Cereno.

“I am very pleased of the research and development efforts that has led to CS585 now being published in the renowned journal Blood. We have received great recognition from the medical community following the publication of this paper about the unique properties of CS585. The fact that this paper has now been selected to be featured in the podcast and awarded a commentary says a lot about CS585’s promising preclinical data presented in the paper,” said Sten R. Sörensen, CEO of Cereno Scientific.

The Blood Podcast concludes by stating “According to the investigators, this oxylipin analog [CS585] is a highly stable compound that based on the work described here retains the benefit of the prostacyclin receptor agonists while avoiding the limitation related to selectivity and instability. In the paper, the investigators provide evidence that CS585 regulates human platelet function through activation of the prostacyclin receptor and could be a significant milestone to improve anti-thrombotic treatment strategies without bleeding.”

Access to the podcast episode:

American Society of Hematology (2023, November 2). Targeting prostacyclin to inhibit platelet activation; MRD-tailored myeloma maintenance; AREG and HSC function in DNA damage repair deficiency and aging [Audio podcast episode]. In Blood Podcast. https://share.transistor.fm/s/b149c73b

Access to a commentary:

Matthew T. Rondina; Targeting prostacyclin: all gain with no pain?. Blood 2023; 142 (18): 1506–1507. doi: https://doi.org/10.1182/blood.2023022227

Access to the paper:
Livia Stanger, Adriana Yamaguchi, Pooja Yalavarthi, Sylviane Lambert, Devin Gilmore, Andrew Rickenberg, Catherine Luke, Kiran Kumar, Andrea T Obi, Andrew White, Niklas Bergh, Bjorn Lennart Dahlof, Michael Holinstat; The oxylipin analogue CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptor. Blood 2023; blood.2023020622. doi: https://doi.org/10.1182/blood.2023020622

For further information, please contact:

Tove Bergenholt, Director IR & Communications

Email: tove.bergenholt@cerenoscientific.com

Phone: +46 732-366 246

Sten R. Sörensen, CEO

Email: sten.sorensen@cerenoscientific.com

Phone: +46 73-374 03 74

About Cereno Scientific AB

Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1’s safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects, selected for prevention of thrombosis as target indication. In preclinical studies, it has been documented to regulate platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. Thrombosis prevention in venous or arterial and cardiovascular disease has been selected as the first indication area for CS014. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.